Analyst on an average expected net profit of Rs 306 crore and net sales of Rs 2,385 crore for the quarter ended March 31, 2013 (Q4). The pharmaceutical company had reported net profit of Rs 156 crore and net sales of Rs 1,883 crore during the same quarter of previous year.
“Lupin is expected to register a strong revenue growth of 32.8% mainly on back of strong growth from US and domestic markets. Its EBIDTA is expected to expand by 350bp during the period. On account of which the net profit is to increase by 89.2% in 4QFY2013,” says analyst at Angel Broking.
“We expect an 300bps uptake in EBIDTA margin on the back of Niche product launches and ramp up in market share of exclusive and limited competition products,” says analyst at Antique Stock Broking.
The stock opened at Rs 720 and has seen combined around 515,169 shares changing hands on the counter till early noon deals on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
